Home › Funds › BIOS Capital Management, LP › LTRN

BIOS Capital Management, LP position in LTRN

LANTERN PHARMA · Health Care

BIOS Capital Management, LP reported holding 235,895 shares of LTRN (LANTERN PHARMA) in its Q3 2026 13F filing — a position valued at US$238.3M, representing 0.70% of its reported portfolio and ranking #5 among its reported holdings. BIOS Capital Management, LP has disclosed LTRN holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

Latest position (Q3 2026)235.90K sh
Reported value held$238.25M
Portfolio Weight0.70%
First reportedQ4 2024
Last changeReduce
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How BIOS Capital Management, LP's LTRN position evolved

BIOS Capital Management, LP first disclosed a stake in LTRN in Q4 2024 at 1,207,709 shares (US$3.9M). The position peaked in Q3 2026 at 235,895 shares, worth US$238.3M. Across 8 filings, BIOS Capital Management, LP increased the stake 0 time(s), trimmed it 6 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 235,895 shares valued at US$238.3M — a reduction of -13,502 shares quarter over quarter.. Notable position changes include a 71% trim in Q2 2026 (shares fell 76% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2024 1.21M $3.85M New
Q1 2025 1.21M $4.28M Hold
Q2 2025 1.08M $3.40M Reduce
Q3 2025 1.02M $4.42M Reduce
Q4 2025 1.01M $3.06M Reduce
Q1 2026 864.43K $1.18M Reduce
Q2 2026 249.40K $1.04M Reduce
Q3 2026 235.90K $238.25M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About LTRN and 13F data

LTRN (LANTERN PHARMA) is a Health Care company. 23 other funds we track also report a position in LTRN — the largest reported positions include Empery Asset Management, LP (US$3.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding LTRN

All LTRN fund holders →

FAQ

How long has BIOS Capital Management, LP held LTRN?

BIOS Capital Management, LP has disclosed LTRN holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

What is BIOS Capital Management, LP's current position in LTRN?

As of Q3 2026, BIOS Capital Management, LP holds 235.90K shares of LTRN (LANTERN PHARMA), valued at $238.25M, representing 0.70% of its reported portfolio and ranking #5.

Has BIOS Capital Management, LP been buying or selling LTRN?

In the latest 13F filing (Q3 2026), BIOS Capital Management, LP reduced its position in LTRN. The position peaked in Q3 2026 at 235.90K shares.

Which other funds hold LTRN?

Other major institutional holders of LTRN include Empery Asset Management, LP, among 23 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.